Express Scripts (ESRX) Guides FY16 EPS Above Expectations

Express Scripts Holding Company (Nasdaq: ESRX) anticipates achieving adjusted earnings per diluted share for 2016 in the range of $6.08 to $6.28, representing growth of 10% to 14% over the mid-point of our previously issued 2015 guidance range – See table below.

*** The Street sees FY16 EPS of $6.04.

"Our focused model of alignment has positioned us uniquely in the healthcare services landscape to improve health outcomes and lower costs for our clients and patients," said George Paz, CEO and chairman of Express Scripts. "No one matches our focus on serving clients and patients and we remain confident in our continued growth and returning exceptional results to our shareholders."

"The fundamentals of our business allow us to deliver solid financial results while making investments to continue our growth as a leading independent PBM and healthcare provider," said Tim Wentworth, President. "We have an aligned book of business and a deep set of innovative solutions to help clients and patients. As we create value for our patients and clients, we create value for our shareholders."

The Company also reaffirms its previously issued 2015 adjusted earnings per diluted share guidance range, which represents growth of 13% to 14% over 2014 and reaffirms all other previously issued 2015 financial guidance.

For further information regarding the guidance above, see "Non-GAAP Financial Measures" below.

You May Also Be Interested In